Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematologyยท2026
Same author

Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial.

British journal of haematologyยท2026
Same author

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

The New England journal of medicineยท2026
Same author

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discoveryยท2026
Same author

EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway.

Haematologicaยท2026
Same author

Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry.

Scientific reportsยท2026
Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Researchยท2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Researchยท2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Researchยท2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Researchยท2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Researchยท2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Researchยท2026
See all related articles

Related Experiment Video

Updated: Sep 28, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.7K

Predicting the Future: Machine-Based Learning for MRD Prognostication.

Charlotte Pawlyn1, Faith E Davies2

  • 1The Institute of Cancer Research, London, United Kingdom.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 31, 2022
PubMed
Summary
This summary is machine-generated.

Minimal residual disease (MRD) detection is crucial for predicting outcomes in multiple myeloma. Identifying factors like tumor burden and biomarkers can improve early prediction and guide personalized treatment strategies.

More Related Videos

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.0K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.4K

Related Experiment Videos

Last Updated: Sep 28, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.7K
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.0K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.4K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Minimal residual disease (MRD) detection is a validated prognostic marker in multiple myeloma.
  • Predicting MRD negativity is key to refining prognostic models and treatment strategies.

Discussion:

  • Factors influencing MRD negativity include tumor burden, cytogenetics, and immune biomarkers.
  • Understanding these predictors can enhance outcome prediction at the time of diagnosis.

Key Insights:

  • Biomarkers and cytogenetic profiles are significant predictors of MRD negativity in multiple myeloma.
  • Early identification of prognostic factors aids in tailoring treatment approaches.

Outlook:

  • Further research into predictive biomarkers can lead to more personalized treatment strategies for multiple myeloma patients.
  • Improved outcome prediction at diagnosis will facilitate tailored therapeutic interventions.